This is a preview of subscription content, log in via an institution to check access.
Reference
Vitz M, et al. New Zealand may finally get funded access to diabetes drugs which reduce cardiovascular events and progression of kidney disease: an audit of proposed PHARMAC criteria compared with international guidelines. New Zealand Medical Journal 133: 76-86, No. 1523, 9 Oct 2020
Rights and permissions
About this article
Cite this article
Access to newly funded T2DM drugs would benefit patients most in need in New Zealand. PharmacoEcon Outcomes News 865, 3 (2020). https://doi.org/10.1007/s40274-020-7227-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7227-1